Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07570082 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
A Phase 1 study, sponsored by Crinetics Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT07570082 is a Phase 1 study that is active but no longer recruiting, run by Crinetics Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT07570082, a Phase 1 study, is active but no longer recruiting, sponsored by Crinetics Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
Interventions
- DRUG Midazolam
- DRUG Metformin
- DRUG Atumelnant
- DRUG Digoxin
- DRUG Carbamazepine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07570082
The ClinicalTrials.gov registry entry for NCT07570082 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT07570082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07570082 about?
NCT07570082 is a clinical study titled "Drug-Drug Interaction Study of Atumelnant in Healthy Participants". This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
What is the current status of trial NCT07570082?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2026-05-28. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07570082?
The interventions under investigation include: Midazolam (DRUG), Metformin (DRUG), Atumelnant (DRUG), Digoxin (DRUG), Carbamazepine (DRUG).
Who is sponsoring clinical trial NCT07570082?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.